Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 3/20 | 0.35 |
| ▸ | FPR2 | P25090 | 3/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478337 | 0.89 | F10 (0.43) | F10CYP2D6CYP2C9GRIN2BFPR1 | |
| SCHEMBL4489285 | 0.84 | F10 (0.41) | F10GRIN2B | |
| SCHEMBL4476098 | 0.80 | F10 (0.43) | F10 | |
| SCHEMBL4478092 | 0.77 | F10 (0.47) | F10FPR1FPR2 | |
| SCHEMBL4478089 | 0.74 | F10 (0.51) | F10FPR1FPR2 | |
| SCHEMBL4475723 | 0.71 | F10 (0.45) | F10 | |
| SCHEMBL8327057 | 0.71 | F10 (0.45) | F10 | |
| SCHEMBL4486077 | 0.71 | F10 (0.45) | F10 | |
| SCHEMBL5794813 | 0.71 | F10 (0.52) | F10FPR1FPR2 | |
| SCHEMBL4490372 | 0.70 | F10 (0.45) | F10FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | SMALLHEER JOANNE M | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, F5 | F10 38/4885CYP2D6 3245/4885CYP2C9 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.